KIT and gastrointestinal stromal tumor: Using two analytically highly sensitive liquid biopsy ctDNA assays (BEAMing and SafeSEQ), both of which reliably allow the for the determination of true KIT mutational status in patients with GIST in the third-line setting, the presence of multi-clonal lesions harboring KIT mutations after prior TKI treatment was seen.